Document Detail

Serial in vivo intravascular ultrasound-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation insights from the ABSORB B trial.
MedLine Citation:
PMID:  22192369     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: This study sought to investigate quantitative and homogeneity differential echogenicity changes of the ABSORB scaffold (1.1) during the first year after implantation.
BACKGROUND: The imaging of the ABSORB bioresorbable vascular scaffold degradation by intravascular ultrasound (IVUS) has previously demonstrated diminishing gray-level intensity of the struts over time that can be evaluated by IVUS-based differential echogenicity. The first generation of ABSORB (1.0) showed a 50% reduction in hyperechogenicity at 6 months and restoration of the pre-ABSORB implantation values at 2 years. The second generation of ABSORB (1.1), investigated in the ABSORB B trial, was modified to prolong the duration of luminal scaffolding.
METHODS: A total of 63 patients were examined by IVUS immediately post-implantation and at 6-month (Cohort B1, n = 28) or 12-month (Cohort B2, n = 35) follow-up. IVUS-based tissue composition analysis software was used to quantify changes in hyperechogenicity over time in the scaffolded regions. Relative changes in hyperechogenicity were calculated as: 100 × (% hyperechogenicity at follow-up - % hyperechogenicity at baseline)/% hyperechogenicity at baseline.
RESULTS: At 6- and 12-month follow-up, there was a 15% (from 22.58 ± 9.77% to 17.42 ± 6.69%, p = 0.001) and 20% (from 23.51 ± 8.57% to 18.25 ± 7.19%, p < 0.001) reduction in hyperechogenicity, respectively, compared with post-implantation values. No difference in hyperechogenicity changes were observed between the proximal, medial, or distal part of the scaffolded segment.
CONCLUSIONS: Quantitative differential echogenicity changes of the ABSORB scaffold (1.1) during the first 12 months after implantation are lower compared with those previously observed with its first generation (1.0), confirming the value of the manufacturing changes and suggesting a slower degradation rate of the scaffold.
Salvatore Brugaletta; Josep Gomez-Lara; Patrick W Serruys; Vasim Farooq; Robert Jan van Geuns; Leif Thuesen; Dariusz Dudek; Jacques Koolen; Bernard Chevalier; Dougal McClean; Stephan Windecker; Pieter C Smits; Bernard de Bruyne; Robert Whitbourn; Ian Meredith; Ron T van Domburg; Kenij Sihan; Sebastiaan de Winter; Susan Veldhof; Karine Miquel-Hebert; Richard Rapoza; Hector M Garcia-Garcia; John A Ormiston; Nico Bruining
Related Documents :
2019499 - Biological half-life of gaseous elemental iodine deposited onto rice grains.
22074549 - The benefit of the reverse transfer function in the fitting process of the vibrant soun...
21787499 - Effect of light-emitting diode photopolymerization modes on the push-out bond strength ...
9497709 - The use of the periotest value as the initial success criteria of an implant: 8-year re...
10786149 - Setting shrinkage and hygroscopic expansion of resin-modified glass-ionomer in experime...
22419269 - Mechanism for the amorphisation of diamond.
7751059 - Resistance to fracture of endodontically treated premolars restored with new generation...
11307879 - Inhibition and reversal of salmonella typhimurium attachment to poultry skin using zinc...
7092029 - Histopathologic examination of a globe containing an intraocular implant.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  JACC. Cardiovascular interventions     Volume:  4     ISSN:  1876-7605     ISO Abbreviation:  JACC Cardiovasc Interv     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-12-23     Completed Date:  2012-04-23     Revised Date:  2014-09-05    
Medline Journal Info:
Nlm Unique ID:  101467004     Medline TA:  JACC Cardiovasc Interv     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1281-9     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Absorbable Implants*
Angioplasty, Balloon, Coronary / adverse effects,  instrumentation
Cardiovascular Agents / administration & dosage*
Coronary Artery Disease / diagnosis,  therapy*
Coronary Vessels / ultrasonography*
Drug-Eluting Stents*
Middle Aged
Predictive Value of Tests
Prosthesis Design
Sirolimus / administration & dosage,  analogs & derivatives*
Time Factors
Treatment Outcome
Ultrasonography, Interventional*
Reg. No./Substance:
0/Cardiovascular Agents; 0/Metals; 159351-69-6/everolimus; W36ZG6FT64/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-elu...
Next Document:  A high-risk period for cerebrovascular events exists after transcatheter aortic valve implantation.